Iannone Robert
Iannone Robert, EVP, GHR, D, CMO, reported an open-market or private sale at Jazz Pharmaceuticals plc involving 18113.000000 shares for an estimated $4528572.41. Reported holdings after the transaction were 94884.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Aug 27, 2026
- Filing date
- Aug 31, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 112,997 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
JAZZ price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001737329-26-000016 Ordinary Shares
- Transaction date
- Aug 27, 2026 Filed Aug 31, 2026, 10:45 PM · 4d delay
- Shares
- 18,113 sh $250.02 per share
- Estimated value
- -$4.52M Computed from shares × price
- Holdings after
- 94,884 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-4 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
EVP, Global Head of R&D & CMO
- F1
This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred…
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby…
- F3
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby…
- F4
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby…
- F5
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person here…
- F6
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person here…
- F7
These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1…
- F8
These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29,…
0 other transactions
0 recent txs